Mylan has announced that it will acquire Meda, which markets a number of OINDPs, including Dymista, Astelin, and Astepro nasal sprays; the Aerospan MDI; and the Novopulmon Novolizer and Formatris Novolizer DPIs. Meda had previously rejected acquisition by Mylan, but the Meda board now recommends that shareholders accept the offer, which is valued at SEK 60.3 billion … [Read more...] about Meda to be acquired by Mylan
News
Medical Developments International acquires Breath-A-Tech
Australian device company Medical Developments International (MVP) has acquired Australian spacer company Breath-A-Tech from Avita Medical for A$2.47 million, comprised of A$2.029 million cash up front and 117,894 shares of MVP stock, which will be escrowed for 6 months, the company said. Breath-A-Tech's products include the Breath-A-Tech spacer and the Funhaler … [Read more...] about Medical Developments International acquires Breath-A-Tech
Fraunhofer ITEM acquires Takeda inhaled surfactant technology
The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) has acquired Takeda's Surfactant and Continuous Powder Aerosolization (CPA) program, the company said. According to the announcement, the transfer took place as Takeda shut down its respiratory department; Takeda sold its core respiratory business to AstraZeneca in December 2015. According … [Read more...] about Fraunhofer ITEM acquires Takeda inhaled surfactant technology
Cirrus Pharmaceuticals announces new inhaler manufacturing services
CDMO Cirrus Pharmaceuticals, a subsidiary of Kemwell, has announced the availability of cGMP inhaler manufacturing services for early phase clinical trials materials at its new facility in Raleigh-Durham, NC. Cirrus announced in October 2014 that it was investing in a new manufacturing suite for a variety of dosage forms, including OINDPs. Cirrus VP of R&D Andrew … [Read more...] about Cirrus Pharmaceuticals announces new inhaler manufacturing services
Rhinocort nasal spray now available over the counter in the US
Johnson & Johnson subsidiary McNeil Consumer Healthcare says that Rhinocort budesonide nasal spray is now available over the counter in the US for the treatment of allergic rhinitis. McNeil acquired the OTC rights to AstraZeneca's Rhinocort Aqua in 2014. McNeil Consumer Healthcare Group Brand Director Purvi Farahi commented, “For consumers who are suffering from … [Read more...] about Rhinocort nasal spray now available over the counter in the US
Septodont to promote Egalet’s Sprix nasal spray to US dentists
Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a share of profits from net sales. Sprix was approved by the FDA in 2010 for short-term treatment of moderate-to-severe pain. Its … [Read more...] about Septodont to promote Egalet’s Sprix nasal spray to US dentists
MannKind says it may partner on Afrezza but will retain full rights
MannKind Corporation held an investor call on February 3, 2016 in which CEO Matt Pfeffer said that the company might co-promote Afrezza inhaled insulin with a partner or partners after Sanofi returns the rights, but that MannKind would retain full rights to the product and will market Afrezza itself after the transition, which is anticipated to occur around April 5, … [Read more...] about MannKind says it may partner on Afrezza but will retain full rights
Spiriva Respimat now available in the US for the treatment of asthma
Spiriva Respimat is now available in US pharmacies for the treatment of asthma, Boehringer Ingelheim has announced. The FDA approved Spiriva Respimat for the treatment of asthma in patients aged 12 and older in September 2015. The tiotropium bromide soft mist inhaler was approved by the FDA for the treatment of COPD in September 2014 and has been available in the … [Read more...] about Spiriva Respimat now available in the US for the treatment of asthma
Discovery Labs appoints Craig Fraser as President and CEO, provides update on Aerosurf program
Discovery Laboratories, which recently released positive Phase 2a data for its Aerosurf aerosolized KL4 surfactant and advanced the product into Phase 2b, has announced the appointment of Craig Fraser as President and CEO. Fraser was most recently Chief Operating Officer of Aegerion Pharmaceuticals and previously held positions at Pfizer, Wyeth, and Johnson & Johnson. … [Read more...] about Discovery Labs appoints Craig Fraser as President and CEO, provides update on Aerosurf program
OptiNose selected for Norwegian grant to study intranasal narcolepsy therapy
OptiNose has been selected by the Research Council of Norway for a grant of up to NOK 15.9 million ($1.8 million) to study intranasal delivery of Orexin-A for the treatment of narcolepsy. The grant is contingent on reaching a contract agreement between the Research Council, OptiNose, and its partners, which include Oslo University Hospital, Smerud Medical Research, … [Read more...] about OptiNose selected for Norwegian grant to study intranasal narcolepsy therapy